| LILRB4 regulates multiple myeloma development through STAT3-PFKFB1 pathway. | LILRB4 regulates multiple myeloma development through STAT3-PFKFB1 pathway.
Xie L, Chen C, Zhang T, Yang W, Zheng D, Cao L, Yuan J, Xu Y, Zhang Y, Liu L, Liang A, Yu Z, Zheng J., Free PMC Article | 08/19/2024 |
| LILRB4 on multiple myeloma cells promotes bone lesion by p-SHP2/NF-kappaB/RELT signal pathway. | LILRB4 on multiple myeloma cells promotes bone lesion by p-SHP2/NF-κB/RELT signal pathway.
Wang H, Wang L, Luan H, Xiao J, Zhao Z, Yu P, Deng M, Liu Y, Ji S, Ma J, Zhou Y, Zhang J, Meng X, Zhang J, Zhao X, Li C, Li F, Wang D, Wei S, Hui L, Nie S, Jin C, An Z, Zhang N, Wang Y, Zhang CC, Li Z., Free PMC Article | 07/23/2024 |
| Downregulation of LILRB4 Promotes Human Aortic Smooth Muscle Cell Contractile Phenotypic Switch and Apoptosis in Aortic Dissection. | Downregulation of LILRB4 Promotes Human Aortic Smooth Muscle Cell Contractile Phenotypic Switch and Apoptosis in Aortic Dissection.
Xiong J, Wang L, Xiong X, Deng Y. | 03/15/2024 |
| LILRB4 Checkpoint for Immunotherapy: Structure, Mechanism and Disease Targets. | LILRB4 Checkpoint for Immunotherapy: Structure, Mechanism and Disease Targets.
Xiang Z, Yin X, Wei L, Peng M, Zhu Q, Lu X, Guo J, Zhang J, Li X, Zou Y., Free PMC Article | 02/28/2024 |
| LILRB4 regulates the function of decidual MDSCs via the SHP-2/STAT6 pathway during Toxoplasma gondii infection. | LILRB4 regulates the function of decidual MDSCs via the SHP-2/STAT6 pathway during Toxoplasma gondii infection.
Li Y, Guo J, Zhang H, Li Z, Ren Y, Jiang Y, Liu X, Hu X., Free PMC Article | 07/24/2023 |
| Blockade of checkpoint ILT3/LILRB4/gp49B binding to fibronectin ameliorates autoimmune disease in BXSB/Yaa mice. | Blockade of checkpoint ILT3/LILRB4/gp49B binding to fibronectin ameliorates autoimmune disease in BXSB/Yaa mice.
Su MT, Inui M, Wong YL, Takahashi M, Sugahara-Tobinai A, Ono K, Miyamoto S, Murakami K, Itoh-Nakadai A, Kezuka D, Itoi S, Endo S, Hirayasu K, Arase H, Takai T. | 02/5/2022 |
| Upregulation of leukocyte immunoglobulin-like receptor B4 on interstitial macrophages in COPD; their possible protective role against emphysema formation. | Upregulation of leukocyte immunoglobulin-like receptor B4 on interstitial macrophages in COPD; their possible protective role against emphysema formation.
Mitsune A, Yamada M, Fujino N, Numakura T, Ichikawa T, Suzuki A, Matsumoto S, Mitsuhashi Y, Itakura K, Makiguchi T, Koarai A, Tamada T, Endo S, Takai T, Okada Y, Suzuki S, Ichinose M, Sugiura H., Free PMC Article | 01/29/2022 |
| ILT3 (LILRB4) Promotes the Immunosuppressive Function of Tumor-Educated Human Monocytic Myeloid-Derived Suppressor Cells. | ILT3 (LILRB4) Promotes the Immunosuppressive Function of Tumor-Educated Human Monocytic Myeloid-Derived Suppressor Cells.
Singh L, Muise ES, Bhattacharya A, Grein J, Javaid S, Stivers P, Zhang J, Qu Y, Joyce-Shaikh B, Loboda A, Zhang C, Meehl M, Chiang DY, Ranganath SH, Rosenzweig M, Brandish PE. | 01/15/2022 |
| Leukocyte immunoglobulin-like receptor B1 and B4 (LILRB1 and LILRB4): Highly sensitive and specific markers of acute myeloid leukemia with monocytic differentiation. | Leukocyte immunoglobulin-like receptor B1 and B4 (LILRB1 and LILRB4): Highly sensitive and specific markers of acute myeloid leukemia with monocytic differentiation.
Churchill HRO, Fuda FS, Xu J, Deng M, Zhang CC, An Z, Zhang N, Chen P, Bergstrom C, Kansagra A, Collins R, John S, Koduru P, Chen W. | 01/8/2022 |
| LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy. | LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy.
Sharma N, Atolagbe OT, Ge Z, Allison JP., Free PMC Article | 10/16/2021 |
| ILT3 promotes tumor cell motility and angiogenesis in non-small cell lung cancer. | ILT3 promotes tumor cell motility and angiogenesis in non-small cell lung cancer.
Li J, Gao A, Zhang F, Wang S, Wang J, Wang J, Han S, Yang Z, Chen X, Fang Y, Jiang G, Sun Y. | 08/7/2021 |
| LILRB4 ITIMs mediate the T cell suppression and infiltration of acute myeloid leukemia cells. | LILRB4 ITIMs mediate the T cell suppression and infiltration of acute myeloid leukemia cells.
Li Z, Deng M, Huang F, Jin C, Sun S, Chen H, Liu X, He L, Sadek AH, Zhang CC., Free PMC Article | 06/5/2021 |
| LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agents. | LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agents.
Chien KS, Class CA, Montalban-Bravo G, Wei Y, Sasaki K, Naqvi K, Ganan-Gomez I, Yang H, Soltysiak KA, Kanagal-Shamanna R, Do KA, Kantarjian HM, Garcia-Manero G., Free PMC Article | 05/1/2021 |
| The observed inflammation was mainly due to BMDM-induced NF-kappaB signaling. In conclusion, our study demonstrates that LILRB4 deficiency plays a detrimental role in ALI-associated BMDM activation by prompting the NF-kappaB signal pathway. | Leukocyte immunoglobulin-like receptor B4 deficiency exacerbates acute lung injury via NF-κB signaling in bone marrow-derived macrophages.
Qiu T, Zhou J, Wang T, Chen Z, Ma X, Zhang L, Zou J., Free PMC Article | 08/12/2020 |
| LILRB4 expression is decreased in hypertrophic hearts. | Leukocyte immunoglobulin-like receptor B4 (LILRB4) negatively mediates the pathological cardiac hypertrophy by suppressing fibrosis, inflammation and apoptosis via the activation of NF-κB signaling.
Li Q, Wei G, Tao T. | 10/12/2019 |
| Our data demonstrate that anti-LILRB4 CAR-T cells specifically target monocytic acute myeloid leukemia cells with no toxicity to normal hematopoietic progenitors. | A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML.
John S, Chen H, Deng M, Gui X, Wu G, Chen W, Li Z, Zhang N, An Z, Zhang CC., Free PMC Article | 08/17/2019 |
| LILRB4 orchestrates tumour invasion pathways in monocytic leukaemia cells by creating an immunosuppressive microenvironment; LILRB4 represents a compelling target for the treatment of monocytic AML | LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration.
Deng M, Gui X, Kim J, Xie L, Chen W, Li Z, He L, Chen Y, Chen H, Luo W, Lu Z, Xie J, Churchill H, Xu Y, Zhou Z, Wu G, Yu C, John S, Hirayasu K, Nguyen N, Liu X, Huang F, Li L, Deng H, Tang H, Sadek AH, Zhang L, Huang T, Zou Y, Chen B, Zhu H, Arase H, Xia N, Jiang Y, Collins R, You MJ, Homsi J, Unni N, Lewis C, Chen GQ, Fu YX, Liao XC, An Z, Zheng J, Zhang N, Zhang CC., Free PMC Article | 04/6/2019 |
| Results suggest that ILT3 played an important role in tumor progression in colorectal cancer by possible influence on CD45RO+ T cells in the tumor microenvironment. | Expression of ILT3 predicts poor prognosis and is inversely associated with infiltration of CD45RO+ T cells in patients with colorectal cancer.
Liu J, Lu CX, Zhang F, Lv W, Liu C. | 11/10/2018 |
| These results suggest that tyrosine phosphorylation may be critical in FcgammaRI-dependent endocytosis/phagocytosis that may be regulated by LILRB4 by triggering dephosphorylation of key signalling proteins. | Leukocyte immunoglobulin-like receptor B4 regulates key signalling molecules involved in FcγRI-mediated clathrin-dependent endocytosis and phagocytosis.
Park M, Raftery MJ, Thomas PS, Geczy CL, Bryant K, Tedla N., Free PMC Article | 04/14/2018 |
| ILT3 may functionally contribute to a regulatory network controlling tumor progression by suppressing the Akt pathway. | Ectopic ILT3 controls BCR-dependent activation of Akt in B-cell chronic lymphocytic leukemia.
Zurli V, Wimmer G, Cattaneo F, Candi V, Cencini E, Gozzetti A, Raspadori D, Campoccia G, Sanseviero F, Bocchia M, Baldari CT, Kabanova A. | 11/18/2017 |
| The ILT3 PBs/PCs were suggested to be developmentally equivalent based on the simultaneous generation of these populations upon activation of memory B cells in vitro ILT3 expression was found to be induced efficiently by IL-2, while IFN-alpha effectively induced ILT3 PBs/PCs in vitro Utilizing the elevated ILT3 will support opening a new avenue for molecular markers for, pathogenic cells. | Tolerogenic immunoreceptor ILT3/LILRB4 paradoxically marks pathogenic auto-antibody-producing plasmablasts and plasma cells in non-treated SLE.
Inui M, Sugahara-Tobinai A, Fujii H, Itoh-Nakadai A, Fukuyama H, Kurosaki T, Ishii T, Harigae H, Takai T. | 11/4/2017 |
| this study shows that LILRB4 might have dual inhibitory and activating functions, depending on the position of the functional tyrosine residues in its immunoreceptor tyrosine-based inhibitory motifs and/or the nature of the stimuli | A dual positive and negative regulation of monocyte activation by leukocyte Ig-like receptor B4 depends on the position of the tyrosine residues in its ITIMs.
Park M, Liu RW, An H, Geczy CL, Thomas PS, Tedla N. | 05/13/2017 |
| LILRB4 expression is significantly upregulated in human masticatory mucosa during wound healing | Human gingiva transcriptome during wound healing.
Wang Y, Tatakis DN. | 03/22/2017 |
| Identification of ILT4 as a cellular receptor for CSP C4d | Ig-like transcript 4 as a cellular receptor for soluble complement fragment C4d.
Hofer J, Forster F, Isenman DE, Wahrmann M, Leitner J, Hölzl MA, Kovarik JJ, Stockinger H, Böhmig GA, Steinberger P, Zlabinger GJ. | 08/27/2016 |
| involvement of ILT3 and ILT4 in the modulation of immune responsiveness in multiple sclerosis by both interferon and vitamin D | Interferon beta and vitamin D synergize to induce immunoregulatory receptors on peripheral blood monocytes of multiple sclerosis patients.
Waschbisch A, Sanderson N, Krumbholz M, Vlad G, Theil D, Schwab S, Mäurer M, Derfuss T., Free PMC Article | 09/12/2015 |